Literature DB >> 12101443

Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology.

D G Charteris1, C S Sethi, G P Lewis, S K Fisher.   

Abstract

Proliferative vitreoretinopathy (PVR) remains a difficult management problem despite advances in vitreoretinal surgery. There is still a significant incidence of PVR in rhegmatogenous retinal detachment and other forms of retinal disease. Surgery for PVR now has a high anatomical success rate although visual results are often disappointing. The use of adjunctive treatments to prevent cellular proliferation holds promise for the prevention of PVR or recurrences after surgery. Control of proliferation and strategies aimed at improving visual outcome are important areas of future research in PVR and other forms of retinal disease. Studies of the intraretinal and peri-retinal pathology of PVR have demonstrated characteristic changes which may have a significant influence on visual outcome and surgical management.

Entities:  

Mesh:

Year:  2002        PMID: 12101443     DOI: 10.1038/sj.eye.6700194

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  50 in total

1.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

2.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

3.  Comparative transcriptomic analysis reveals adriamycin-induced apoptosis via p53 signaling pathway in retinal pigment epithelial cells.

Authors:  Yu-Chen Lin; Ze-Ren Shen; Xiao-Hui Song; Xin Liu; Ke Yao
Journal:  J Zhejiang Univ Sci B       Date:  2018 Dec.       Impact factor: 3.066

4.  Vitrectomy with and without scleral buckle for inferior retinal detachment.

Authors:  Y Y Y Kwong; C W Tsang; W W Lai; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

5.  Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).

Authors:  Shawn A Morales; Sergey Mareninov; Paige Coulam; Madhuri Wadehra; Lee Goodglick; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

Review 6.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

7.  Fibronectin and focal adhesion kinase small interfering RNA modulate rat retinal Müller cells adhesion and migration.

Authors:  Xin-Ling Wang; Tao Yu; Jin-Song Zhang; Qi-Chang Yan; Ya-Hong Luo
Journal:  Cell Mol Neurobiol       Date:  2009-01-27       Impact factor: 5.046

8.  Expression of IGFBP-6 in a proliferative vitreoretinopathy rat model and its effects on retinal pigment epithelial cell proliferation and migration.

Authors:  Hong-Mei Zhao; Min-Jie Sheng; Jing Yu
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

9.  Interaction of monocarboxylate transporter 4 with beta1-integrin and its role in cell migration.

Authors:  Shannon M Gallagher; John J Castorino; Nancy J Philp
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-10       Impact factor: 4.249

10.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.